Report Description Table of Contents How Are Selective AXL Inhibitors, Treatment-Resistance Strategies, and Clinical Developments Shaping the Global AXL Receptor Tyrosine Kinase Inhibitors Market? – (Updated On: 16th-Nov-2026) According to Strategic Market Research, the Global AXL Receptor Tyrosine Kinase Inhibitors Market was valued at USD 3.37 billion in 2025 and is projected to reach USD 4.72 billion by 2032, growing at a CAGR of 4.9% during 2026–2032. The market encompasses selective AXL inhibitors, AXL-active multikinase medicines, and emerging AXL-directed therapies being developed to address resistance to existing cancer treatments. Pharmaceutical companies are investigating these medicines in combination with chemotherapy, targeted therapies, and immunotherapy, particularly for patients with advanced or treatment-resistant cancers. AXL is a protein involved in tissue repair, immune regulation, and the removal of dead cells through interactions with GAS6. In certain cancers, increased AXL activity contributes to tumor progression and resistance to established medicines. This has encouraged pharmaceutical companies to develop treatments that block AXL activity and potentially improve responses to existing cancer therapies. Clinical development is creating new opportunities for the market, with Arcus Biosciences' AB801, SignalChem Lifesciences' SLC-391, and Exelixis' zanzalintinib representing notable investigational programs. While selective AXL inhibitors remain in clinical development, zanzalintinib has advanced to regulatory review for metastatic colorectal cancer. Future market opportunities will depend on successful approvals, demonstrated treatment benefits, and the adoption of AXL-directed medicines within established oncology regimens. How Are Selective AXL Inhibitors Advancing Toward Commercial Development? Selective AXL inhibitor development is gaining attention as pharmaceutical companies investigate treatments for cancers that become resistant to existing medicines. Arcus Biosciences is advancing AB801, also known as ligritinib, as an oral selective AXL inhibitor being evaluated alongside established chemotherapy and immunotherapy treatments. Unlike approved multikinase medicines that inhibit several cancer-related targets, AB801 is being developed specifically to assess the contribution of AXL inhibition to treatment outcomes. In June 2026, a Phase I/1b trial of AB801 was registered for pancreatic adenocarcinoma and cholangiocarcinoma, with an estimated enrollment of 46 patients. The study evaluates AB801 alongside established cancer medicines, including chemotherapy and immunotherapy combinations. Its estimated primary completion date is June 2027. The program provides a defined development pathway for selective AXL inhibition, although clinical effectiveness and commercial eligibility remain to be established. SignalChem Lifesciences is pursuing a similar opportunity through SLC-391. In December 2025, published Phase I results involving 35 patients with advanced solid tumors showed that 12 patients, or 34.3%, achieved stable disease, with disease stabilization lasting up to 318 days. These findings support continued investigation of SLC-391 in treatment-resistant cancers, while the early-stage results have not yet demonstrated superiority over existing therapies. The progression of AB801 and SLC-391 is important for the market because selective AXL medicines do not yet have the established commercial position enjoyed by approved oncology kinase inhibitors. Successful later-stage trials could create a distinct therapeutic category in which drug revenue is directly attributable to AXL inhibition rather than broader multikinase activity. Can AXL-Targeted Combination Therapies Overcome Resistance to Existing Cancer Treatments? Combining AXL inhibitors with established anticancer medicines is becoming a major development strategy, particularly in cancers where patients experience disease progression after earlier treatment. Pharmaceutical companies are investigating whether AXL inhibition can improve responses to chemotherapy, immunotherapy, and targeted medicines rather than requiring the introduction of entirely new treatment regimens. Arcus Biosciences' AB801 program provides a direct example of this approach. Its registered Phase I trial includes combinations with gemcitabine, cisplatin, and durvalumab in cholangiocarcinoma, alongside a chemotherapy and zimberelimab-based regimen in pancreatic cancer. The study is designed to determine whether AB801 can be added to these treatments at acceptable doses and generate evidence supporting further clinical development. SignalChem Lifesciences has also investigated SLC-391 in combination with pembrolizumab for advanced or metastatic non-small cell lung cancer. This development direction is commercially relevant because immunotherapy is already established in lung cancer treatment, potentially allowing a successful AXL inhibitor to be introduced as an additional component of existing regimens. The opportunity for manufacturers will depend on demonstrating that AXL inhibition produces measurable benefits beyond the medicines already being administered. Combination treatments may also require additional expenditure and safety monitoring, making improvements in clinical outcomes essential for future reimbursement and prescribing decisions. How Is Zanzalintinib's Regulatory Progress Influencing the AXL-Active Kinase Inhibitor Landscape? Exelixis' zanzalintinib represents one of the most advanced investigational multikinase medicines with AXL inhibitory activity. The drug targets AXL alongside several other kinase pathways, distinguishing it from selective AXL inhibitors such as AB801 and SLC-391. In the Phase III STELLAR-303 trial, zanzalintinib combined with atezolizumab demonstrated median overall survival of 10.9 months, compared with 9.4 months for regorafenib, in previously treated metastatic colorectal cancer. The combination achieved a 20% reduction in the risk of death in the overall study population, with a hazard ratio of 0.80 and a p-value of 0.0045. These findings supported regulatory submission and demonstrated the potential of zanzalintinib as an additional cancer treatment. However, the clinical benefit cannot be attributed specifically to AXL inhibition because zanzalintinib acts on multiple targets and was evaluated alongside immunotherapy. In June 2026, the final analysis involving patients without active liver metastases showed a favorable but statistically nonsignificant survival trend, with a hazard ratio of 0.83. This introduced additional uncertainty into the overall clinical assessment. In September 2026, the U.S. FDA extended the review period for zanzalintinib combined with atezolizumab after Exelixis submitted updated safety and efficacy information. The revised regulatory decision date is March 3, 2027. The regulatory outcome will be significant for the broader AXL-active multikinase landscape. A potential approval could strengthen commercial interest in medicines that include AXL among their therapeutic targets, although it would not establish the effectiveness of selective AXL inhibition independently. Are AXL-Targeted Antibody-Drug Conjugates Creating New Development Opportunities? The development of AXL-targeted antibody-drug conjugates is broadening pharmaceutical interest beyond conventional AXL kinase inhibitors. These investigational medicines use AXL as a target for delivering anticancer treatment to selected tumor cells, representing a different development strategy from oral inhibitors. BioAtla's mecbotamab vedotin (BA3011) is an investigational AXL-targeted antibody-drug conjugate that has undergone clinical evaluation in solid tumors, including non-small cell lung cancer and sarcoma. Its development demonstrates how AXL can be used for targeted drug delivery rather than solely for blocking cancer-related signaling. For pharmaceutical manufacturers, AXL-targeted ADCs represent a potential opportunity to compete in cancer indications where existing therapies provide insufficient disease control. Their future commercial position will depend on treatment outcomes, patient eligibility, safety, and differentiation from approved ADC medicines. GAS6-targeting biologics also represent an alternative approach to AXL-directed treatment development. Batiraxcept has been investigated as a GAS6-binding treatment intended to prevent activation of AXL. However, clinical setbacks in this program demonstrate the risks associated with translating AXL-related treatment strategies into approved products. The inclusion of ADCs and GAS6-directed medicines broadens the competitive landscape, but these products should be distinguished from selective AXL kinase inhibitors when estimating market revenues. An AXL-targeted ADC and a small-molecule AXL inhibitor are separate therapeutic products, even though both are associated with the same receptor. Which Pharmaceutical Companies Are Building Competitive Positions in AXL Inhibitor Development? The competitive landscape is concentrated among companies developing selective AXL inhibitors, AXL-active multikinase medicines, and alternative AXL-targeting therapies. Arcus Biosciences, SignalChem Lifesciences, Exelixis, BioAtla, and Qurient represent different development approaches, with their commercial prospects determined by clinical maturity, product differentiation, and the progress of their respective programs. Arcus Biosciences is developing AB801 as a selective AXL inhibitor, with current clinical investigation focused on combination treatments in pancreatic cancer and cholangiocarcinoma. Its competitive opportunity lies in demonstrating that specifically inhibiting AXL can improve outcomes when added to established therapies. SignalChem Lifesciences is advancing its selective AXL development strategy through SLC-391. The company's published Phase I results demonstrated stable disease in 12 of 35 patients, providing an initial clinical basis for combination studies. Its future position will depend on whether subsequent trials establish stronger evidence of treatment effectiveness. Exelixis has a more advanced development position through zanzalintinib, which is undergoing FDA review for metastatic colorectal cancer. In 2026, the company also expanded the zanzalintinib clinical program through additional studies involving colorectal cancer and lung cancer. Its commercialization experience with cabozantinib provides an established oncology foundation, although neither cabozantinib revenue nor potential zanzalintinib revenue should be classified entirely as selective AXL inhibitor sales. BioAtla has investigated AXL-targeted drug delivery through mecbotamab vedotin, while Qurient has evaluated Q702, an oral multikinase inhibitor targeting AXL, MER, and CSF1R. BerGenBio provides an important example of development risk. In June 2025, the company discontinued its remaining bemcentinib development activities after concluding that continued investment lacked sufficient financial justification. Its decision demonstrates that selective AXL inhibitors must establish convincing clinical benefits and viable development pathways to attract sustained commercial investment. What Do Recent AXL Inhibitor Clinical Trials Reveal About Future Market Opportunities? Recent AXL-related clinical developments show a contrast between programs approaching regulatory decisions and selective inhibitors that remain in earlier clinical evaluation. In August 2026, Exelixis initiated the Phase III STELLAR-316 trial involving zanzalintinib in patients with resected stage II/III colorectal cancer who tested positive for molecular residual disease. Conducted in collaboration with Merck and Natera, the study is investigating whether treatment with an AXL-active multikinase medicine can improve outcomes in a defined patient population. In October 2026, Exelixis initiated the Phase II STELLAR-202 trial evaluating zanzalintinib combined with pembrolizumab as maintenance treatment for squamous non-small cell lung cancer. The trial expands the potential indications being investigated for zanzalintinib, although any future approval would depend on clinical findings across the drug's multiple therapeutic targets. Selective AXL inhibitor development is progressing through smaller studies. AB801 is being evaluated in combination with chemotherapy and immunotherapy, while SLC-391 has generated preliminary evidence supporting further clinical investigation. These programs remain relevant to the future market because they could establish indications in which AXL inhibition is the primary therapeutic objective. The contrasting outcomes of bemcentinib and ongoing selective AXL programs also highlight investment risks. Clinical progress alone does not guarantee regulatory approval or commercial viability, particularly when investigational medicines must demonstrate benefits beyond established oncology treatments. Will Selective AXL Inhibitors Establish a Standalone Commercial Market? The AXL Receptor Tyrosine Kinase Inhibitors Market remains an emerging therapeutic category in which investigational selective inhibitors and AXL-active multikinase medicines have different levels of development maturity. Near-term regulatory activity is concentrated around zanzalintinib, while selective inhibitors such as AB801 and SLC-391 represent longer-term commercialization opportunities. AXL-targeted antibody-drug conjugates and GAS6-directed medicines may expand treatment options, but their future contribution depends on successful clinical development. The most important determinant of a standalone AXL inhibitor market will be whether selective medicines achieve regulatory approval for clearly defined cancer indications. Such approvals would establish identifiable product sales attributable directly to AXL inhibition, rather than relying on revenues from broader multikinase treatments. Future commercial opportunities will therefore depend on the outcomes of selective AXL inhibitor trials, the success of combination treatment strategies, competitive differentiation, and evidence supporting use in defined patient populations. Companies that demonstrate clear additional clinical benefits from AXL inhibition will be best positioned to establish commercial demand in this emerging oncology drug category. AXL Receptor Tyrosine Kinase Inhibitors Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 3.37 Billion Revenue Forecast in 2032 USD 4.72 Billion Overall Growth Rate CAGR of 4.9% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Inhibitor Type, By Cancer Indication, By Treatment Approach, By Route of Administration, By End User, By Geography By Inhibitor Type Selective AXL Inhibitors, Multi-Target AXL Inhibitors, Dual Kinase Inhibitors By Cancer Indication Non-Small Cell Lung Cancer (NSCLC), Acute Myeloid Leukemia (AML), Hepatocellular Carcinoma (HCC), Other Cancer Indications By Treatment Approach Monotherapy, Immunotherapy Combinations, Chemotherapy Combinations By Route of Administration Oral Administration, Intravenous Administration, Other Administration Routes By End User Hospitals, Specialty Oncology Clinics, Cancer Research Institutes By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Development of therapies addressing cancer treatment resistance, clinical investment in selective AXL inhibitors, evaluation of chemotherapy and immunotherapy combinations, advancement of AXL-active multikinase therapies Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving growth across the AXL Receptor Tyrosine Kinase Inhibitors Market? A1. Growth is supported by increasing research into treatment-resistant cancers, selective AXL inhibitors, combination oncology regimens, and emerging AXL-directed therapies targeting advanced solid tumors. Q2. Why are selective AXL inhibitors gaining importance in the industry? A2. Selective inhibitors such as AB801 and SLC-391 are being developed to determine whether direct AXL blockade can improve outcomes in treatment-resistant cancers and establish a distinct commercial category beyond multikinase therapies. Q3. How are combination therapies shaping future market opportunities? A3. AXL inhibitors are being investigated alongside chemotherapy, immunotherapy, and targeted medicines. Commercial adoption will depend on demonstrating measurable clinical benefits beyond established treatment regimens. Q4. Why is zanzalintinib important to the AXL-active inhibitor landscape? A4. Zanzalintinib is among the most advanced AXL-active multikinase candidates and is under FDA review for metastatic colorectal cancer. Its regulatory outcome could strengthen commercial interest in therapies that include AXL among their targets. Q5. How are AXL-targeted antibody-drug conjugates expanding the treatment landscape? A5. AXL-targeted ADCs such as mecbotamab vedotin use AXL to deliver anticancer treatment to selected tumor cells, creating an alternative development pathway beyond conventional small-molecule kinase inhibition. Q6. What will determine whether selective AXL inhibitors establish a standalone commercial market? A6. A standalone market will depend on successful late-stage trials, regulatory approvals, clearly defined cancer indications, and evidence that selective AXL inhibition provides meaningful additional clinical benefit over existing therapies. Sources: Arcus Biosciences – Identifies AB801 as an Investigational AXL Inhibitor Being Developed to Address AXL-Mediated Resistance to Established Cancer Treatments Arcus Biosciences – AB801 AXL Inhibitor Development Program U.S. National Cancer Institute – Lists an Active Phase I Trial Evaluating AB801 With Chemotherapy and Immunotherapy in Pancreatic Cancer and Cholangiocarcinoma NCI – AB801 Combination Therapy Trial in Pancreatic and Biliary Cancers SignalChem Lifesciences – Its December 18, 2025 Announcement Reported Stable Disease in 12 of 35 Patients Receiving SLC-391, With Disease Stabilization Lasting Up to 318 Days SignalChem – First-in-Human Phase I Results for Selective AXL Inhibitor SLC-391 U.S. National Cancer Institute – Documents Investigation of SLC-391 With Pembrolizumab in Advanced Non-Small Cell Lung Cancer; the Trial Is Listed as Administratively Complete NCI – SLC-391 and Pembrolizumab Combination Study Exelixis – STELLAR-303 Results Reported Median Overall Survival of 10.9 Months With Zanzalintinib Plus Atezolizumab Versus 9.4 Months With Regorafenib, With a 20% Reduction in Death Risk Exelixis – Detailed Phase III STELLAR-303 Results, October 20, 2025 Exelixis – June 22, 2026 Results Showed a Statistically Nonsignificant Survival Trend in STELLAR-303 Patients Without Active Liver Metastases, With a Hazard Ratio of 0.83 Exelixis – Final STELLAR-303 Analysis in the Non-Liver-Metastases Subpopulation Exelixis / U.S. SEC – A September 10, 2026 Filing Confirmed That FDA Extended the Zanzalintinib–Atezolizumab Review, Setting March 3, 2027 as the Revised Target Action Date SEC – Exelixis Filing on Zanzalintinib Regulatory Review Extension Exelixis – Initiated Phase III STELLAR-316 in August 2026 to Evaluate Zanzalintinib With or Without Pembrolizumab-Based Therapy in Molecular Residual Disease-Positive Colorectal Cancer Exelixis – Third-Quarter 2026 Update: STELLAR-316 Clinical Development Exelixis – Initiated Phase II STELLAR-202 in October 2026, Evaluating Zanzalintinib With Pembrolizumab as Maintenance Treatment for Squamous Non-Small Cell Lung Cancer Exelixis – Third-Quarter 2026 Filing: STELLAR-202 Trial Initiation BioAtla – Identifies Mecbotamab Vedotin, BA3011, as an AXL-Targeted Antibody-Drug Conjugate Investigated in Solid Tumors Including Non-Small Cell Lung Cancer and Sarcoma BioAtla – Mecbotamab Vedotin and AXL-Targeted ADC Portfolio U.S. National Cancer Institute – Documents Qurient’s Completed Phase I Study of Q702, an Oral Inhibitor Targeting AXL, MER, and CSF1R, in Advanced Solid Tumors NCI – Q702 Multikinase Inhibitor Clinical Trial BerGenBio – Announced on June 3, 2025, That It Would Discontinue All Remaining Bemcentinib Development Activities Because Continued Development Lacked Sufficient Financial Justification BerGenBio – Bemcentinib Development Discontinuation and Strategic Review Table of Contents - Global AXL Receptor Tyrosine Kinase Inhibitors Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, and End User Competitive Positioning of Selective AXL Inhibitors and AXL-Active Multikinase Medicines Investment Opportunities in the AXL Receptor Tyrosine Kinase Inhibitors Market Key Clinical Developments and Innovations Strategic Partnerships and Oncology Development Collaborations High-Growth Segments for Investment Opportunities in Selective AXL Inhibitors, AXL-Active Multikinase Medicines, and AXL-Targeted Antibody-Drug Conjugates Investment Potential in Combination Therapies and Treatment-Resistance Strategies Emerging Opportunities in GAS6-Directed Biologics and AXL-Targeted Drug Delivery Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Biological Role of AXL Receptor Tyrosine Kinase and GAS6 Signaling Role of AXL Inhibition in Tumor Progression and Cancer Treatment Resistance Strategic Importance of AXL-Directed Therapies in Chemotherapy, Targeted Therapy, and Immunotherapy Combinations Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Clinical Pipeline and Regulatory Development Assessment Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Clinical Trial Outcomes and Regulatory Developments Role of Selective AXL Inhibition in Addressing Resistance to Existing Cancer Treatments Impact of Combination Strategies Involving Chemotherapy, Targeted Therapies, and Immunotherapy Clinical Differentiation Between Selective AXL Inhibitors and AXL-Active Multikinase Medicines Commercial Potential of AXL-Targeted Antibody-Drug Conjugates and GAS6-Directed Biologics Global AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type: Selective AXL Inhibitors AXL-Active Multikinase Inhibitors Dual Kinase Inhibitors Market Analysis by Cancer Indication: Pancreatic Cancer Cholangiocarcinoma Non-Small Cell Lung Cancer Metastatic Colorectal Cancer Sarcoma Other Solid Tumors Market Analysis by Treatment Approach: Monotherapy Chemotherapy Combinations Immunotherapy Combinations Targeted Therapy Combinations Market Analysis by Route of Administration: Oral Administration Intravenous Administration Market Analysis by End User: Hospitals Specialty Oncology Clinics Cancer Research Institutes Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, and End User Country-Level Breakdown: United States Canada Mexico Europe AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa AXL Receptor Tyrosine Kinase Inhibitors Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Arcus Biosciences SignalChem Lifesciences Exelixis, Inc. BioAtla, Inc. Qurient Co., Ltd. BerGenBio ASA Merck & Co., Inc. Genentech, Inc. Natera, Inc. Gilead Sciences, Inc. Pfizer Inc. Bristol Myers Squibb AstraZeneca plc Novartis AG Competitive Landscape and Strategic Insights Benchmarking Based on Clinical Pipeline Maturity, Selectivity, Target Profile, Combination Potential, and Regulatory Progress Selective AXL Inhibitor Development and Commercial Positioning AXL-Active Multikinase Medicine Portfolio Positioning AXL-Targeted Antibody-Drug Conjugate Development GAS6-Directed Biologics and Alternative AXL-Targeting Strategies Clinical Trial and Regulatory Benchmarking: AB801, SLC-391, Zanzalintinib, Mecbotamab Vedotin, Q702, and Bemcentinib Combination Therapy Strategies in Chemotherapy, Immunotherapy, and Targeted Oncology Treatments Clinical and Regulatory Developments During 2025 and 2026 Emerging Commercial Opportunities and Development Risks Through 2032 Appendix Abbreviations and Terminologies Used in the Report References and Sources Clinical Trial and Regulatory Development References (2025–2026) Market Definitions and Segmentation Criteria List of Tables Market Size by Inhibitor Type, Cancer Indication, Treatment Approach, Route of Administration, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading AXL Inhibitor Developers Clinical Pipeline Assessment of Selective AXL Inhibitors and AXL-Active Multikinase Medicines Clinical Development and Regulatory Status of AB801, SLC-391, Zanzalintinib, Mecbotamab Vedotin, Q702, and Bemcentinib AXL-Targeted Combination Therapy and Treatment-Resistance Development Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Inhibitor Type, Cancer Indication, Treatment Approach, and End User (2025 vs. 2032) Global AXL Receptor Tyrosine Kinase Inhibitors Ecosystem and Value Chain Analysis Selective AXL Inhibitor and AXL-Active Multikinase Development Landscape Clinical Development Pathways for AB801, SLC-391, and Zanzalintinib AXL-Targeted Antibody-Drug Conjugate and GAS6-Directed Therapeutic Approaches